MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-05-2024
Catalent Cash Conversion Cycle 2011-2025 | CTLT
Annual Cash Conversion Cycle Catalent
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110 | 124 | 105 | 96.9 | 92.1 | 108 | 90.2 | 94.6 | 88.3 | 79.1 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 124 | 79.1 | 98.8 |
Quarterly Cash Conversion Cycle Catalent
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.2 | - | 113 | 117 | 129 | - | 129 | 124 | 129 | 58.3 | 96.8 | 96.6 | 110 | 47.8 | 87.3 | 85.6 | 87.4 | 84.4 | 82.6 | 88 | 95.6 | 87.9 | 90.3 | 88.8 | 95.8 | 77.7 | 78.9 | 71.3 | 81 | 73.6 | 71.7 | 70 | 81.6 | 78.2 | 77 | 64.2 | 73.4 | 74.7 | 76.5 | 66.9 | 80.3 | 80.8 | 44 | - | 39.4 | 32.3 | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 129 | 32.3 | 84.1 |
Cash Conversion Cycle of other stocks in the Drug manufacturers industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alimera Sciences
ALIM
|
-128 | - | - | $ 142 M |  USA |
 |
Assertio Holdings
ASRT
|
327 | $ 0.74 | -3.53 % | $ 52.6 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
460 | - | - | $ 754 M | USA |
 |
Canopy Growth Corporation
CGC
|
177 | $ 1.69 | -3.13 % | $ 182 M |  Canada |
 |
AcelRx Pharmaceuticals
ACRX
|
-58.9 | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-224 | - | 0.86 % | $ 117 M | USA |
 |
Cronos Group
CRON
|
213 | $ 3.06 | -6.57 % | $ 1.61 B | Canada |
 |
Agile Therapeutics
AGRX
|
-206 | - | 10.11 % | $ 58.2 M | USA |
 |
Aurora Cannabis
ACB
|
1.45 K | $ 5.18 | -4.17 % | $ 86.3 M | Canada |
 |
HEXO Corp.
HEXO
|
775 | - | 2.45 % | $ 38.1 M | Canada |
 |
DURECT Corporation
DRRX
|
41.4 | - | - | $ 50.1 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
139 | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
141 | - | - | $ 28.9 M |  Irlanda |
 |
Emergent BioSolutions
EBS
|
181 | $ 11.76 | 2.98 % | $ 602 M | USA |
 |
Evoke Pharma
EVOK
|
45.7 | $ 10.97 | 0.18 % | $ 36.7 M | USA |
 |
Athenex
ATNX
|
137 | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
192 | $ 21.39 | 0.14 % | $ 2.04 B |  France |
 |
Evolus
EOLS
|
74.6 | $ 7.17 | 1.85 % | $ 445 M | USA |
 |
Harrow Health
HROW
|
-86.6 | $ 46.47 | -1.25 % | $ 1.52 B | USA |
 |
China Pharma Holdings
CPHI
|
164 | $ 1.55 | -0.64 % | $ 27.1 M |  China |
 |
Bausch Health Companies
BHC
|
78.9 | $ 6.83 | -1.37 % | $ 2.49 B | Canada |
 |
Lannett Company
LCI
|
173 | - | 1.15 % | $ 7.11 M | USA |
 |
Organogenesis Holdings
ORGO
|
64.5 | $ 4.86 | 0.73 % | $ 640 M | USA |
 |
OrganiGram Holdings
OGI
|
2.92 K | $ 1.82 | -5.36 % | $ 402 M | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
-161 | $ 3.03 | 19.57 % | $ 42.6 M | USA |
 |
Pacira BioSciences
PCRX
|
209 | $ 26.71 | 1.6 % | $ 1.24 B | USA |
 |
Rockwell Medical
RMTI
|
45 | $ 0.88 | -5.09 % | $ 20.5 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
150 | $ 3.45 | -3.96 % | $ 4.28 M | USA |
 |
PetIQ
PETQ
|
53.8 | - | 1.64 % | $ 400 M | USA |
 |
Jupiter Wellness
JUPW
|
-21.1 | - | - | $ 33.6 M | USA |
 |
Perrigo Company plc
PRGO
|
138 | $ 12.85 | -2.17 % | $ 1.77 B | USA |
 |
ProPhase Labs
PRPH
|
96 | $ 0.11 | -2.7 % | $ 1.74 M | USA |
 |
Radius Health
RDUS
|
-53.5 | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
105 | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
314 | - | - | $ 1.08 B | USA |
 |
Veru
VERU
|
6.7 | $ 2.43 | 0.41 % | $ 328 M | USA |
 |
PLx Pharma
PLXP
|
111 | - | -27.8 % | $ 2.56 M | USA |
 |
cbdMD
YCBD
|
92 | $ 1.4 | 14.75 % | $ 6.04 M | USA |
 |
SCYNEXIS
SCYX
|
106 | $ 0.64 | -1.21 % | $ 30.6 M | USA |
 |
Tilray
TLRY
|
169 | $ 11.41 | -6.09 % | $ 7.05 B | Canada |
 |
TherapeuticsMD
TXMD
|
-723 | $ 1.69 | -3.43 % | $ 17.6 M | USA |
 |
Zomedica Corp.
ZOM
|
196 | - | -0.21 % | $ 98 M | USA |
 |
Viatris
VTRS
|
155 | $ 11.68 | 0.21 % | $ 14.2 B | USA |